Genitourinary Syndrome of Menopause (GSM)
Understanding vaginal and urinary symptoms of estrogen deficiency, and why they don't improve without treatment
What It Is
Genitourinary Syndrome of Menopause (GSM) is the medical term for vulvovaginal and urinary symptoms caused by estrogen deficiency, typically occurring during and after menopause. GSM includes what was previously called "vulvovaginal atrophy," "vaginal atrophy," and "urogenital atrophy."
GSM affects 50-70% of postmenopausal women. Unlike hot flashes that often improve over time, GSM symptoms worsen without treatment and significantly impact quality of life and sexual function.
Why It Matters
GSM is Significantly Underdiagnosed and Undertreated
- β’ Women often don't bring up symptoms due to embarrassment
- β’ Providers often don't ask about vaginal or urinary symptoms
- β’ Many women think symptoms are "just part of aging" and must be tolerated
- β’ GSM does NOT improve spontaneously and worsens without treatment
- β’ GSM is highly treatable with vaginal estrogen
GSM significantly impacts:
- Sexual function and intimacy - painful intercourse is the most common presenting complaint
- Quality of life - chronic discomfort, burning, irritation
- Urinary health - recurrent UTIs, urgency, frequency
- Relationships - avoidance of intimacy due to pain
Common Symptoms
Vaginal/Vulvar Symptomsβββ
- Vaginal dryness
- Burning, irritation, rawness
- Dyspareunia (painful intercourse) - often the presenting complaint
- Lack of lubrication during intercourse
- Vaginal itching
- Narrowing of vaginal opening
Urinary Symptomsβββ
- Urinary urgency and frequency
- Dysuria (painful urination)
- Recurrent urinary tract infections (UTIs)
- Urinary incontinence (stress or urge)
How GSM Develops
Mechanismβββ
Estrogen deficiency causes:
- β’ Thinning of vaginal epithelium (atrophy)
- β’ Loss of vaginal elasticity and rugae (folds)
- β’ Reduced blood flow to vaginal tissue
- β’ Decreased vaginal secretions
- β’ Vaginal pH increases from ~4.5 to 6-7 (becomes less acidic)
Key point: The pH change alters the vaginal microbiome, losing protective lactobacilli and increasing infection risk (UTIs, bacterial vaginosis).
Why It's Often Underdiagnosed
Barriers to Diagnosis and Treatment:
- Embarrassment: Women hesitate to discuss vaginal/sexual symptoms
- Providers don't ask: Sexual health and vaginal symptoms are often not addressed in routine visits
- Misconception that symptoms are "normal aging": Many women think they must tolerate symptoms
- Confusion with other conditions: Recurrent UTIs or burning may be attributed to infections rather than GSM
- Fear of HRT: Women may avoid treatment due to concerns about hormone therapy (but vaginal estrogen is different from systemic HRT)
How It's Diagnosed
Clinical Diagnosisβββ
GSM is diagnosed based on:
- Symptoms: Vaginal dryness, dyspareunia, urinary symptoms
- Pelvic exam findings:
- β’ Pale, dry, thin vaginal mucosa
- β’ Loss of vaginal rugae (folds)
- β’ Visible blood vessels (friable tissue that bleeds easily)
- β’ Narrowed vaginal introitus
- Vaginal pH testing: pH greater than 5 (normally 3.8-4.5 in premenopausal women)
No blood tests required. Diagnosis is clinical based on symptoms and exam.
Differential Diagnosis
Rule out other causes of vaginal symptoms:
- β’ Infections (yeast, bacterial vaginosis, STIs)
- β’ Dermatologic conditions (lichen sclerosus, lichen planus)
- β’ Vulvodynia (chronic vulvar pain)
- β’ Contact dermatitis
Evidence-Based Treatment
Treatment focuses on restoring vaginal health and estrogen levels. This is educational information only - treatment decisions should be made with your healthcare provider.
Vaginal Estrogen - MOST EFFECTIVEβββ
First-line treatment for GSM. Reverses atrophy, restores vaginal pH, and improves all symptoms.
- β’ Estradiol cream (Estrace)
- β’ Estradiol vaginal tablet (Vagifem)
- β’ Estradiol vaginal ring (Estring) - releases low-dose continuously for 3 months
- β’ Minimal systemic absorption (very low blood levels)
- β’ Safe even in breast cancer survivors in most cases (discuss with oncologist - individualized decision)
- β’ Does NOT require progestogen (unlike systemic HRT)
- β’ Can be used long-term
Prasterone (DHEA Vaginal Insert)βββ
Intrarosa: DHEA insert that converts locally to estrogen and testosterone. FDA-approved for dyspareunia. Alternative to estrogen for some women.
Ospemifene (Oral SERM)βββ
Osphena: Selective estrogen receptor modulator (SERM) taken orally. FDA-approved for moderate-to-severe dyspareunia. Estrogen-agonist effects on vaginal tissue. Alternative to vaginal estrogen.
Non-Hormonal Optionsββ
Less effective than hormonal treatments but may provide some relief:
- Vaginal moisturizers (e.g., Replens): Use regularly (2-3x/week). Provide temporary relief but don't reverse atrophy.
- Vaginal lubricants: Water- or silicone-based. Use during sexual activity. Short-term relief only.
- CO2 laser therapy (MonaLisa Touch) or radiofrequency: Emerging evidence. Expensive, not covered by insurance. More research needed on long-term efficacy.
Key Points About Vaginal Estrogen Safety
Vaginal Estrogen is NOT the Same as Systemic HRTβββ
- Minimal systemic absorption: Vaginal estrogen results in very low blood estrogen levels, far lower than systemic HRT
- Does not require progestogen: Unlike systemic estrogen (which requires progesterone to protect the uterus), vaginal estrogen does not stimulate endometrial growth at therapeutic doses
- Can often be used with history of hormone-sensitive cancer: Individualized decision with oncologist. Many breast cancer survivors can safely use vaginal estrogen due to minimal absorption.
- Can be used long-term: GSM is a chronic condition. Treatment can continue as long as needed.
Importance of Treatment
GSM Does NOT Improve Without Treatment
Unlike hot flashes, which often improve over time:
- β’ GSM symptoms persist and worsen without treatment
- β’ Tissue changes become more pronounced over time
- β’ Quality of life and sexual function continue to decline
- β’ Treatment is highly effective and safe
- β’ There is no need to "just tolerate" these symptoms
What This Page Does NOT Replace
This educational content cannot and does not:
- β’ Diagnose GSM or rule out other causes of vaginal symptoms
- β’ Provide prescriptions or dosing instructions
- β’ Determine whether vaginal estrogen is safe for your specific medical history
- β’ Replace individualized consultation with your healthcare provider
If you have vaginal dryness, painful intercourse, or recurrent UTIs, discuss these symptoms with your healthcare provider. GSM is highly treatable.
Key Takeaways
- GSM affects 50-70% of postmenopausal women but is significantly underdiagnosed
- Unlike hot flashes, GSM does not improve on its own and worsens without treatment
- Vaginal dryness and painful intercourse are the most common presenting symptoms
- Vaginal estrogen is the first-line, most effective treatment and is safe for long-term use
- Vaginal estrogen is NOT the same as systemic HRT and typically does not require progestogen
- Diagnosis is clinical, based on symptoms and pelvic exam - no blood tests required
Related Resources
Premature Ovarian Insufficiency
Women with POI can also develop GSM due to estrogen deficiency
Read More βMedical Advocacy
Scripts for discussing vaginal and sexual health symptoms with providers
Learn More βVulvodynia
Another cause of vulvar pain and dyspareunia - important to distinguish from GSM
Read More βEvidence Summary
Well-Established (βββ)
Prevalence and mechanism of estrogen deficiency, effectiveness and safety of vaginal estrogen, minimal systemic absorption of vaginal formulations, natural history of worsening without treatment
Emerging Evidence (ββ)
Long-term efficacy of CO2 laser therapy and radiofrequency, comparative effectiveness of prasterone and ospemifene versus vaginal estrogen
Research Gaps (β )
Long-term safety data for energy-based devices, optimal treatment protocols for breast cancer survivors on aromatase inhibitors, best strategies for improving screening rates
Last Updated: January 2025